S. Young

发表

Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

C. Yancy, J. Cohn, M. Packer, 2001, New England Journal of Medicine.

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

S. Gottlieb, R. Cody, T. LeJemtel, 1996, Circulation.

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.

J. Cohn, T. LeJemtel, S. Krueger, 1997, Journal of cardiac failure.

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

J. A. Bowers, J. Cohn, S. Krueger, 1996, Circulation.

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

K. Adams, S. Krueger, W. Abraham, 1996, Circulation.

Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial.

J. Deanfield, P. Lichtlen, P. Sellier, 2002, Journal of the American College of Cardiology.

Safety and efficacy of carvedilol in severe heart failure

Milton Packer, Michael R. Bristow, Michael B. Fowler, 1997 .

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

S. Gottlieb, R. Cody, T. LeJemtel, 1996, Circulation.

Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.

G. Oster, J. Cohn, M. Packer, 2001, Journal of the American College of Cardiology.

Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

C. Yancy, J. Cohn, M. Packer, 2001, The New England journal of medicine.